Literature DB >> 2581917

Myelin basic protein and S-100 antigen in cerebrospinal fluid of patients with multiple sclerosis in the acute phase.

A R Massaro, F Michetti, A Laudisio, P Bergonzi.   

Abstract

It has previously been demonstrated that both Myelin Basic Protein (MBP) and S-100 are released in the cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients during acute phases of exacerbation of the disease. In order to investigate the pathobiological significance of the release of these two proteins into the CSF, MBP and S-100 were assayed in 10 MS patients during the five weeks following onset of an acute exacerbation. MBP was detectable in CSF during the first three weeks after exacerbation, while S-100 was detectable during the entire period of observation, at least in some of the patients. MBP reached its highest CSF concentrations during the first two weeks while S-100 did so in the third week, decreasing thereafter. This difference in time of presence of MBP and S-100 in the CSF is probably due to the different biological origin, MBP being a marker of myelin sheath injury, and S-100, more probably, of astrocytic activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2581917     DOI: 10.1007/bf02229218

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  11 in total

1.  The topographical distribution of S-100 and GFA proteins in the adult rat brain: an immunohistochemical study using horseradish peroxidase-labelled antibodies.

Authors:  S K Ludwin; J C Kosek; L F Eng
Journal:  J Comp Neurol       Date:  1976-01-15       Impact factor: 3.215

Review 2.  The design of clinical studies to assess therapeutic efficacy in multiple sclerosis.

Authors:  J R Brown; G W Beebe; J F Kurtzke; R B Loewenson; D H Silberberg; W W Tourtellotte
Journal:  Neurology       Date:  1979-09       Impact factor: 9.910

3.  The nervous system-specific S-100 antigen in cerebrospinal fluid of multiple sclerosis patients.

Authors:  F Michetti; A Massaro; M Murazio
Journal:  Neurosci Lett       Date:  1979-02       Impact factor: 3.046

4.  A soluble protein characteristic of the nervous system.

Authors:  B W Moore
Journal:  Biochem Biophys Res Commun       Date:  1965-06-09       Impact factor: 3.575

5.  The cellular localization of the two brain specific proteins, S-100 and 14-3-2.

Authors:  T J Cicero; W M Cowan; B W Moore; V Suntzeff
Journal:  Brain Res       Date:  1970-02-17       Impact factor: 3.252

6.  Appearance of a brain specific antigen (th S-100 protein) during human foetal development.

Authors:  J E Zuckerman; H R Herschman; L Levine
Journal:  J Neurochem       Date:  1970-02       Impact factor: 5.372

7.  Complement fixation for antigens on a picogram level.

Authors:  B W Moore; V J Perez
Journal:  J Immunol       Date:  1966-06       Impact factor: 5.422

8.  The S-100 antigen in cerebrospinal fluid as a possible index of cell injury in the nervous system.

Authors:  F Michetti; A Massaro; G Russo; G Rigon
Journal:  J Neurol Sci       Date:  1980-01       Impact factor: 3.181

9.  A diagnostic index of active demyelination: myelin basic protein in cerebrospinal fluid.

Authors:  S R Cohen; B R Brooks; R M Herndon; G M McKhann
Journal:  Ann Neurol       Date:  1980-07       Impact factor: 10.422

10.  Myelin encephalitogenic protein fragments in cerebrospinal fluid of persons with multiple sclerosis.

Authors:  J N Whitaker
Journal:  Neurology       Date:  1977-10       Impact factor: 9.910

View more
  7 in total

1.  Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis.

Authors:  P J Jongen; K J Lamers; W H Doesburg; W A Lemmens; O R Hommes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

Review 2.  Cerebrospinal fluid markers in neurological disorders.

Authors:  A R Massaro; G Scivoletto; P Tonali
Journal:  Ital J Neurol Sci       Date:  1990-12

3.  Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis.

Authors:  K Rejdak; A Petzold; T Kocki; J Kurzepa; P Grieb; W A Turski; Z Stelmasiak
Journal:  J Neural Transm (Vienna)       Date:  2007-03-29       Impact factor: 3.575

4.  Four year double-blind controlled study of levamisole in multiple sclerosis.

Authors:  A R Massaro; R P Cioffi; A Laudisio; D Schiavino; M Mariani
Journal:  Ital J Neurol Sci       Date:  1990-12

5.  Repeated intrathecal triamcinolone acetonide administration in progressive multiple sclerosis: a review.

Authors:  Mazen Abu-Mugheisib; Reiner Benecke; Uwe K Zettl
Journal:  Mult Scler Int       Date:  2011-06-26

6.  A lack of association between elevated serum levels of S100B protein and autoimmunity in autistic children.

Authors:  Laila Yousef Al-Ayadhi; Gehan Ahmed Mostafa
Journal:  J Neuroinflammation       Date:  2012-03-16       Impact factor: 8.322

7.  Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a.

Authors:  Ee Tuan Lim; Axel Petzold; Siobhan M Leary; Daniel R Altmann; Geoff Keir; Ed J Thompson; David H Miller; Alan J Thompson; Gavin Giovannoni
Journal:  J Negat Results Biomed       Date:  2004-10-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.